Dianthus Therapeutics (NASDAQ:DNTH) Research Coverage Started at TD Cowen

TD Cowen initiated coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research note released on Friday, MarketBeat.com reports. The brokerage issued a buy rating on the stock.

A number of other brokerages have also recently weighed in on DNTH. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Oppenheimer raised their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Dianthus Therapeutics presently has an average rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Stock Up 3.3 %

DNTH stock opened at $23.80 on Friday. The company has a market cap of $704.48 million, a price-to-earnings ratio of -9.52 and a beta of 1.74. The business has a fifty day simple moving average of $25.69 and a 200-day simple moving average of $26.64. Dianthus Therapeutics has a 52 week low of $7.75 and a 52 week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. As a group, analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC increased its position in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after acquiring an additional 1,124 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Dianthus Therapeutics during the 2nd quarter valued at approximately $112,000. The Manufacturers Life Insurance Company purchased a new stake in Dianthus Therapeutics during the 2nd quarter worth approximately $236,000. Fred Alger Management LLC raised its position in shares of Dianthus Therapeutics by 52.5% in the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after purchasing an additional 3,316 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at approximately $265,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.